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Margherita Russo*, Carmela Rifici, Edoardo Sessa, Giangaetano D’Aleo, Placido Bramanti and Rocco Salvatore CalabròAbstract
Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD),
used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sativex is thought to not affect
cognition or induce any psychiatric problem at the doses generally used. Nonetheless, it is known that the concomitant
use of more than one muscle-relaxant drugs can result in additive neuropsychiatric effects. Herein we describe a case
of a woman affected by MS and treated with baclofen and methylprednisolone, who developed important behavioral
changes, including suicidal ideation, after 4 weeks of Sativex administration. We are not completely able to state if
Sativex alone was responsible for our patient’s psychiatric symptoms, in reason of the concomitant use of the other drugs.
In conclusion, physicians should pay more attention when prescribing drugs to MS patients affected by spasticity,
including Sativex, since neurobehavioral side effects may emerge especially in predisposed individuals.Background
Nabiximols (Sativex) is an oromucosal spray, containing
delta-9 tetrahydrocannabinol (THC) and cannabidiol
(CBD), and commonly used as an add-on treatment for
unresponsive spasticity in multiple sclerosis (MS) pa-
tients. Sativex common side effects include dizziness and
tiredness, whereas psychiatric symptoms, such as anx-
iety, changes in mood, and paranoid ideas, have been
rarely reported [1]. However, at the doses generally used,
Sativex do not affect driving ability or have any signifi-
cant detrimental effects on cognition and mood, also in
aged people, as demonstrated by Rekand [2]. Nonethe-
less, it is known that the concomitant use of more than
one musclerelaxant drugs can result in additive neuro-
psychiatric effects [3]. Indeed baclofen, one of the most
used myorelaxants, may induce numerous neuropsychi-
atric adverse drug reactions, including behavioral disin-
hibition [4]. Moreover, corticosteroids are used in MS
for the management of acute exacerbations because of
their potential activity in reducing inflammation-related
damage in the central nervous system (CNS). Nonethe-
less, methylprednisolone, a frequently used corticoster-
oid, may produce neuropsychiatric effects.* Correspondence: margheritarusso@virgilio.it
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A 55-year-old female, affected since ten years by relaps-
ing remitting MS, according to McDonald 2001 criteria,
and treated with beta-interferon (INF-β) since 2005,
comes to our observation for a clinical relapse character-
ized by ataxia and urinary urgency. In addition, the pa-
tient presented a moderate to severe spasticity partially
responsive to baclofen 50 mg/daily. Family and personal
history was unremarkable, although since adolescence
she reported anxiety with sporadic episodes of depres-
sive mood. Nevertheless, since she was not diagnosed
with any psychiatric illness, including major depression
or bipolar disorders, she has never been treated with any
specific psychoactive drugs. Physical examination was
negative, whereas neurological examination showed mild
ataxia, moderate to severe right hemiparesis with spastic
hypertonia and hypoesthesia, bilateral dysmetria, tetra-
hyperreflexia, and urinary urgency, with an Expanded
Disability Scale of 6, a Modified Ashwort (MAS) of 3+,
Numeric Rating Scale for Spasticity (NRS) of 10, Ambula-
tion Index (AI) of 5. Hematochemical tests, including
autoimmune and thyroid screening, were normal. A brain
and spinal cord MRI showed multiple T2 weighted hyper-
intensities, mainly involving the periventricular and juxta-
cortical areas, and brainstem, with an enhancing-lesion in
the cerebellum. Methylprednisolone 8 mg/daily for 3 days,
followed by 4 mg/ daily for other 3 days, was thus pre-
scribed, with a significant improvement in urinary urgencyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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prescribed Sativex, according to our regional (Sicily) cri-
teria, to improve her severe spasticity, till reaching a daily
dosage of ten puffs (2,7 mg of THC and 2,5 mg of CBD
per single-dose). At one month-follow-up she had a good
response to the treatment, as showed by nearly all the
clinical scales (MAS 3-, NRS 6, AI 5). However, his
husband referred that she presented important behavioral
changes with alternations of maniac and depressive phases,
and suicidal ideation, so to suggest a substance induced
mood disorder. Nabiximol was thus stopped with a complete
remission of psychiatric symptoms within 10 days. During
such period no specific psychiatric drugs were needed, but
only low dose benzodiazepine (0,50 mg alprazolam) to
overcome her insomnia. At 3 month-follow-up she did
not present any psychiatric problem.
Discussion and conclusions
The “probable” role of Sativex in the occurrence of the
psychotic symptoms presented by our patient is demon-
strated by the fact that symptoms appeared after Nabiximol
was introduced, and disappeared after Sativex discontinu-
ation. A total score of 5 (probable) was obtained on the
Naranjo causality scale. The CNS side effects of Nabiximols
are generally mild to moderate, are usually well tolerated,
and tend to disappear with continued therapy, or with re-
duction of initial dosage. Nevertheless, hallucinations, delu-
sional beliefs or transient psychotic reactions have also
been reported. The brain endocannabinoid (eCB) system
modulates several neurobiological processes and its dys-
function is suggested to be involved in the pathophysiology
of mood and drug use disorders. The psychiatric disorders
related to cannabis use are mainly anxiety and depressive
mood, although cannabis use has been linked with the
neurobiology of schizophrenia. Indeed, the CB1 receptor-
mediated signaling has been shown to play a critical role in
the neural circuitry mediating mood, motivation, and emo-
tional behaviors. Moreover, an increase in CB1 receptor
levels is associated with suicide.
Although data on the role of eCB system in the patho-
physiology of major depression and suicide have been
reported, it remains to be clearly understood whether
alterations in the CB1 receptor-mediated signaling in se-
lective brain regions are linked to neurobehavioral disor-
ders, including depressive mood [5].
Moreover, a possible role of the GABA transmission in
the pathophysiology of mood disorders may also be
hypothesizable, since Sativex also act on GABA-B recep-
tors, which in turn have been demonstrated to modulate
serotoninergic neurotransmission.
However, we are not completely able to state if Sativex
alone was responsible for our patient’s psychiatric symp-
toms, as they could be also related to the concomitant use
of baclofen and methylprednisolone. Indeed, baclofen couldhave a complex and indefinite action on the dopaminergic
or serotoninergic system, through which mania may be in-
duced in vulnerable subjects. Notably, many other agents,
including corticosteroids, have the potential for inducing
behavioral side effects.
Emerging evidence have also demonstrated a genetic
contributions to the depressive disorders through family
studies and molecular genetics, with specific additional
events (as a new drug introduction) precipitating depres-
sive illness in such predisposed individuals [6].
In conclusion, physicians should pay more attention
when prescribing drugs to MS patients affected by spas-
ticity, including Sativex, since neurobehavioral side ef-
fects may emerge especially in predisposed individuals.
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